Gensight Biologics SA Aktie
Deine Einschätzung
Gensight Biologics SA Aktie
Was spricht für und gegen Gensight Biologics SA in den nächsten Jahren?
Pro
Kontra
Rendite von Gensight Biologics SA im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Gensight Biologics SA | -1,32 % | -4,79 % | -1,82 % | -30,61 % | -14,79 % | -95,73 % | -78,58 % |
Celsion Corp. | 3,17 % | 0,00 % | -23,75 % | 5,17 % | 65,99 % | -91,74 % | - |
India Globalization Capital | 20,00 % | 4,52 % | -7,50 % | 24,16 % | 41,22 % | -71,00 % | -69,52 % |
CEL-SCI Corp. | -0,45 % | -4,03 % | -20,50 % | -35,10 % | -49,19 % | -93,45 % | - |
Kommentare
News
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
GenSight Biologics Announces its 2024 Financial Calendar
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal